论文部分内容阅读
目的:探讨头孢呋辛联合阿奇霉素治疗慢性阻塞性肺疾病的价值。方法:收集我院慢性阻塞性肺疾病伴感染的患者,分为:研究组(抗菌药物治疗方案为头孢类药物联合阿奇霉素)和对照组(抗菌药物治疗方案为单用头孢类药物)。对比两组慢性阻塞性肺疾病治疗疗效;两组治疗前后血气分析结果。结果:研究组和对照组慢性阻塞性肺疾病治疗有效率分别为95%、89%,结果比较有差异(P<0.05);研究组和对照组治疗前Pa O2、Pa CO2分别为(60.25±12.57mm Hg、65.52±8.41mm Hg)、(61.31±13.57mm Hg、64.87±13.66mm Hg)比较无差异(P>0.05);研究组和对照组治疗后Pa O2、Pa CO(84.52±8.57mm Hg、36.57±5.27mm2Hg)、(72.36±5.87mm Hg、42.35±6.51mm Hg)比较有差异(P<0.05)。结论:头孢呋辛联合阿奇霉素治疗慢性阻塞性肺疾病疗效优于单一头孢呋辛治疗方案。
Objective: To investigate the value of cefuroxime combined with azithromycin in the treatment of chronic obstructive pulmonary disease. Methods: Patients with chronic obstructive pulmonary disease (COPD) infection in our hospital were collected and divided into study group (antibacterial drug treatment combined with cephalosporins and azithromycin) and control group (antibacterial drug treatment alone was cephalosporin). The curative effect of two groups of chronic obstructive pulmonary disease was compared. The blood gas analysis results of two groups before and after treatment. Results: The effective rates of treatment of chronic obstructive pulmonary disease in study group and control group were 95% and 89%, respectively (P <0.05). PaO2 and Pa CO2 in study group and control group were (60.25 ± 12.57mm Hg, 65.52 ± 8.41mm Hg), (61.31 ± 13.57mm Hg, 64.87 ± 13.66mm Hg). There was no significant difference between the two groups (P> 0.05) Hg, 36.57 ± 5.27 mm2Hg), (72.36 ± 5.87 mm Hg, 42.35 ± 6.51 mm Hg) (P <0.05). Conclusion: Cefuroxime plus azithromycin is superior to single cefuroxime in the treatment of chronic obstructive pulmonary disease.